Patent ID: 8350118
Filing Date: 2013-01-08
Classification: A01K

Abstract:
1. A transgenic mouse whose genome comprises a homozygous disruption of its filaggrin gene wherein a region from a translation-initiation site contained in exon 2 through an in-frame ATG contained in exon 3 of the filaggrin gene is systematically and homozygously replaced by a marker gene via a homologous recombination with a targeting vector having the following characteristics (a) to (c): (a) being designed so that the region from the translation-initiation site contained in exon 2 through the in-frame ATG contained in exon 3 of an endogenous gene encoding filaggrin is replaced by the marker gene at the time of homologous recombination; (b) comprising on a 5′ side of the marker gene sequence of the above (a), a gene sequence of 7 kb or more which is homologous to a sequence comprising a 5′-untranslated region of the endogenous gene encoding filaggrin; and (c) comprising on a 3′ side of the marker gene sequence of the above (a), a gene sequence of 1.5 kb or less which is homologous to a sequence downstream of the in-frame ATG contained in exon 3 of the endogenous gene encoding filaggrin, wherein the transgenic mouse exhibits the following phenotypes (i) to (iii): (i) a reduced amount of amino acids in stratum corneum as compared with a wild-type mouse of the same strain; (ii) a higher skin-permeability as compared with a wild-type mouse of the same strain; and (iii) dermatitis that is induced by a mite-allergen sensitization.